Trial Data Asset CENTOGENE’s access to a large genetic database and its catalogue of rare diseases across more than one hundred countries can accelerate patient recruitment, enable biomarker discovery, and support companion diagnostics for pharma partners.

Global Trial Support With operations in many countries and a broad disease scope, CENTOGENE can facilitate multinational clinical trials, simplify regulatory data packages, and provide diverse patient cohorts to global pharma and biotech customers.

Strategic Transaction Signals Recent strategic sale of operating subsidiaries to an affiliate of Charme Capital Partners suggests a potential opening for partnerships, co investments, or asset driven collaborations that leverage CENTOGENE’s data and expertise.

Neuro Leadership Proven expertise in neurodegenerative diseases and Parkinson’s disease genetics, including published studies, positions CENTOGENE as a preferred partner for early target identification, patient stratification, and genetic testing services in CNS programs.

Regional Expansion Regional expansion opportunities exist through Lifera Omics funding and Saudi joint venture links, enabling local partnerships, data collaborations, and joint development initiatives in the Middle East and beyond.